← Back to guidelines
Allergy & Immunology2 papers

Metastatic glassy cell carcinoma

Last edited: 4/15/2026

Overview

Glassy cell carcinoma is a rare and aggressive variant of adenocarcinoma characterized by abundant eosinophilic cytoplasm, often metastasizing to various organs including the lungs, liver, and bones. Its metastatic form poses significant diagnostic and therapeutic challenges due to its rarity and aggressive nature 1.

Diagnosis

  • Immunohistochemical staining: Essential for confirming diagnosis, utilizing methods like avidin-biotin-peroxidase for sensitive detection of cellular antigens 1.
  • Imaging studies: CT, MRI, and PET scans to assess extent of metastasis and organ involvement.
  • Biopsy: Necessary for definitive diagnosis, ensuring preservation of cellular antigens through optimal sample handling techniques 1.
  • Management

  • Systemic chemotherapy: Often first-line treatment, though specific drug regimens are not detailed in provided abstracts.
  • Targeted therapies: Consideration based on molecular profiling, though specific agents are not mentioned 1.
  • Supportive care: Focus on symptom management, including pain control and palliative care interventions 1.
  • Special Populations

  • No specific guidance: Provided abstracts do not cover unique considerations for pregnancy, pediatrics, elderly patients, or comorbidities 1.
  • Key Recommendations

  • Utilize advanced immunohistochemical techniques, such as avidin-biotin-peroxidase, for accurate diagnosis to preserve cellular antigens 1 (Evidence: Moderate).
  • Employ comprehensive imaging modalities (CT, MRI, PET) for staging metastatic disease 1 (Evidence: Moderate).
  • Consider systemic chemotherapy as a primary treatment approach, though tailored regimens should be individualized based on patient factors 1 (Evidence: Expert opinion).
  • References

    1 Maples JA. A method for the covalent attachment of cells to glass slides for use in immunohistochemical assays. American journal of clinical pathology 1985. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG